Brief: Maia Biotechnology Reports Updates On Preliminary Survival Data For Thio-101 Phase 2 Trial For Advanced Non-Small Cell Lung Cancer
10/07/2023 13:03
Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY REPORTS UPDATES ON PRELIMINARY SURVIVAL
DATA
FOR THIO-101 PHASE 2 TRIAL FOR ADVANCED NON-SMALL CELL LUNG
CANCER
* MAIA BIOTECHNOLOGY INC - NO NEW SAFETY ANALYSIS WAS
CONDUCTED
* MAIA BIOTECHNOLOGY INC - FIRST 2 PATIENTS DOSED WITH THIO
CONTINUE TO BE WITHOUT DOCUMENTED PROGRESSION FOR 12.2 AND 11.5
MONTHS
Source text for Eikon: ID:nBw2y9MQHa
Further company coverage: MAIA.A
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale